Skip to main content

Table 1 Timeline schedule for participants: screen, intervention, and follow-up

From: Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial

 

Screening

Baseline/Enrollment Visit 0 (V0)

Treatment visit 1 (V1)

Follow up visit 2 (V2, week 6)

Follow up visit 3 (V3, week 12)

Follow up visit 4 (V4, week 24)

Follow up visit 5 (V5, week 36)

Follow up visit 6 (V6, week 48)

Follow up visit 7 (V7, week 60)

Follow up visit 8 (V8, week 72)

Follow up visit 9 (V9, week 84)

Follow up visit 10 (V10, week 96)

Informed consent form

 

✓

          

Randomization

 

✓

          

Demographics

✓

           

Medical history

✓

           

Physical examinationa

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Vital signs

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Performance status

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Concomitant medications

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Hemotologyb

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Serum biochemistryc

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

Hepatic disease examinationd

✓

✓

          

Abdominal CT or MRI

✓

   

✓

 

✓

 

✓

 

✓

 

Whole-body CT scan

     

✓

 

✓

 

✓

 

✓

EKG (as indicated)

✓

           

Fibrosis evaluation (Acoustic Radiation Force Impulse; ARFI)

 

✓

          

Pregnancy test (urine)e

 

✓

          

Adverse event evaluation

  

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

  1. aInclusion of physical examinations for abdominal condition, ascites, encephalopathy, body temperature, weight, height, pulse, and blood pressure
  2. bInclusion of CBC/DC, PLT, WBC classification, ANC, and PT/APTT
  3. cInclusion of AST, ALT, Albumin, alkaline phosphatase, LDH, total protein, total bilirubin, direct bilirubin, BUN, Cr, sodium ([NA+]), potassium ([K+]), AFP, GGT, INR
  4. dInclusion of HBsAg and Anti-HCV. Note that the following items are selective: HBeAg, HBeAb, HBcAg, HBV DNA, and HCV-RNA
  5. eWomen with childbearing potential only
  6. Note 1: It was desirable to follow the study calendar as outlined, despite progression disease (PD). For per monthly tests, +/− 1 week was permitted, and for per 3, 6 and 12 monthly tests, +/− 2 weeks were permitted
  7. Note 2: This table was modified from recommendation of SPIRIT 2013 [46]
  8. Abbreviation: CBC/DC complete blood count/differential count, PLT platelet, WBC white blood cell, ANC absolute neutrophil count, PT/APTT prothrombin time/activated partial thromboplastin time, AST Aspartate Aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, BUN blood urea nitrogen, Cr Creatinine, AFP alpha-fetoprotein, GGT γ-Glutamyltransferase, INR international normalized ratio, HAV hepatitis A virus, HBsAg hepatitis B surface antigen, HCV hepatitis C virus, CT computed tomography, MRI magnetic resonance imaging